Business, energy, technology, markets and global industry news from Business News Today

social anxiety disorder

PharmaDeviceNews social anxiety disorder
Representative image: Otsuka’s centanafadine Phase 3b results highlight the investigational ADHD treatment’s potential in adults with comorbid anxiety ahead of the FDA decision.
Pharma & Biotech

Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?

Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.

Read More
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More